About NeuroBioPharm

NeuroBioPharm researches and develops novel proprietary active pharmaceutical ingredients for cognitive and neurological conditions. The conditions range from brain development applications to various neurodegenerative diseases and include:

  • Attention-Deficit Hyperactivity Disorder (ADHD)
  • Autism
  • Alzheimer's disease and its different stages
  • Cognitive decline

The Company is advancing its product portfolio of bioactive ingredients of through the pharmaceutical development pathway which includes prescription medical foods (MF), over-the-counter products (OTC), and prescription drugs (Rx). NeuroBioPharm seeks corporate partnerships, strategic alliances and research collaborations adding value to its research and development, financial and/ or commercialization capabilities.

A product portfolio of proprietary composition of astaxanthin and novel long-chain omega-3 phospholipids are sourced from sustainable abundant marine biomass including Antarctic krill (Euphausia superba). Phospholipids are the major component of cell membranes and essential for all vital cell processes. They are one of the principle constituents of the brain and have been proven to be the preferred carriers of DHA to the erythrocytes and the brain . It has been proposed that the changes in neurotransmitter function that have been associated with psychiatric conditions of this type may in some cases be secondary to changes in the lipid composition of neuronal phospholipids1.

NeuroBioPharma’s proprietary composition of astaxanthin and novel phospholipids carry and functionalize EPA and DHA stabilized by potent antioxidants. Evidence has demonstrated the anti-inflammatory properties of EPA and DHA regulating very important biological functions including degenerative, arthritic, circulatory, digestive, and brain diseases. It is well documented that aging and high oxidative stress lead to a deterioration of the human internal antioxidant defense systems. Astaxanthin is the only carotenoid and one of very few antioxidants that cross the blood brain barrier and penetrate in the brain. Studies have proven a neuroprotective effect improving cognitive function caused by brain damage or age related to phospholipids and astaxanthin2-7.
  • 1 Horrobin DF (1999) The phospholipid concept of psychiatric disorders. In Phospholipid Spectrum disorder
    in Psychiatry, pp. 3–20 [M Peet, I Glen and DF Horrobin, editors]. Carnforth, Lancs.: Marius Press.
  • 2 Lagarde M, Bernoud N, Brossard N, et al. Lysophosphatidylcholine as a preferred carrier form of
    docosahexaenoic acid to the brain. J Mol Neurosci. 2001; 16: 201-4.
  • 3 Wainwright PE. Dietary essential fatty acids and brain function: a developmental perspective on
    mechanisms. Proc Sci Nutr. 2002; 61: 61-69.
  • 4 Hussein, G., Nakamura, M., Zhao, Q., Iguchi, T., Goto, H., Sankawa, U., Watanabe, H. (2005).
    “Antihypertensive and neuroprotective effects of astaxanthin in experimental animals.”
    Biological and Pharmaceutical Bulletin. 28(1):47-52.
  • 5 Kudo, Y., Nakajima, R., Matsumoto, N. (2002). “Effects of astaxanthin on brain damages due to ischemia”
    Carotenoid Science. 5,25.
  • 6 Oryza Oil & Fat Chemical Company. (2006). “Natural Antioxidant for Neuro-protection,
    Vision Enhancement & Skin Rejuvenation.” September 7, 2006.
  • 7 Tso, M., Lam, T. (1996) “Method of Retarding and Ameliorating Central Nervous System and Eye Damage.”
    U.S. Patent #5527533.
 

in this section

About NeuroBioR&D;
Medical Need

NeuroBioPharm researches and develops novel proprietary active pharmaceutical ingredients for neurological conditions.